<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9343">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05700045</url>
  </required_header>
  <id_info>
    <org_study_id>KY-20222263-F-1</org_study_id>
    <nct_id>NCT05700045</nct_id>
  </id_info>
  <brief_title>TAP Using Dexmedetomidine and Ropivacaine for Cesarean Section Analgesia</brief_title>
  <official_title>Effect of Dexmedetomidine Combined With Ropivacaine Transverse Abdominal Plane Block (TAP) on Opioid Dosage After Cesarean Section Under Multimodal Analgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of dexmedetomidine as an adjuvant of ropivacaine in the TAP block on&#xD;
      cesarean section parturients under multimodal analgesia, optimize the multimodal analgesia&#xD;
      program for cesarean section, and guide perioperative analgesia managemen。This is a single&#xD;
      center, double-blind, randomized clinical trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 31, 2023</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Consumption of hydromorphone</measure>
    <time_frame>48 hours after surgery</time_frame>
    <description>Consumption of hydromorphone 48 hours after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Consumption of hydromorphone</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>Consumption of hydromorphone 24 hours after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First time to press bolus</measure>
    <time_frame>48 hours after surgery</time_frame>
    <description>Time between end of surgery and first time to press bolus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attempts of pressing bolus</measure>
    <time_frame>48 hours after surgery</time_frame>
    <description>Attempts of pressing bolus at 4 hours, 12 hours, 24 hours and 48 hours after surgery respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numeric Rating Scale</measure>
    <time_frame>48 hours after surgery</time_frame>
    <description>Numeric rating scale sores at rest , ambulation and uterine contraction. Postoperative pain will be scored on a scale of 0 to 10 on the NRS, with nil (0) representing no pain and 10 representing the worst imaginable pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative satisfaction</measure>
    <time_frame>48 hours after surgery</time_frame>
    <description>Self-planned satisfaction with postoperative analgesia 0 point: dissatisfied, persistent pain, unable to sleep;&#xD;
point: satisfied, slight pain, pain when breathing deeply or coughing;&#xD;
points: very satisfied, painless when breathing deeply or coughing, quiet to sleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Ramsay score</measure>
    <time_frame>48 hours after surgery</time_frame>
    <description>It divides a patient's level of sedation into six categories ranging from severe agitation to deep coma. Level 1 sober: the patient is anxious, restless or irritable; Level 2 sober: the patient is cooperative, has good orientation or is quiet; Level 3 sober: the patient only responds to commands; Level 4 sleep: the patient responds quickly to light tapping between the eyebrows or strong sound stimulation; Grade 5 sleep: the patient is slow to respond to light tapping between the eyebrows or strong sound stimulation; Grade 6 sleep: the patient has no response to light tapping between the eyebrows or strong sound stimulation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>48 hours after surgery</time_frame>
    <description>Incidence of adverse events after surgery, eg, pruritus, postoperative nausea and vomiting, dizziness, and respiratory depression</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of rescue analgesia</measure>
    <time_frame>48 hours after surgery</time_frame>
    <description>Parturient women with the NRS at rest&gt;3 points or the NRS with movement&gt;6 points will be given hydromorphone 0.3-0.5mg for rescue analgesia</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Multimodal Analgesia</condition>
  <condition>Cesarean Section</condition>
  <arm_group>
    <arm_group_label>dexmedetomidine + ropivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>each side dexmedetomidine 0.5ug/kg+0.25% ropivacaine 20ml TAP block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ropivacaine</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>each side 0.25% ropivacaine 20ml TAP block</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>each side dexmedetomidine 0.5ug/kg TAP block</description>
    <arm_group_label>dexmedetomidine + ropivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1) 37-42 weeks of gestation&#xD;
&#xD;
             2) Plan cesarean section&#xD;
&#xD;
             3) Receiving patient controlled intravenous analgesia&#xD;
&#xD;
             4) Age&gt;18 years&#xD;
&#xD;
             5) ASA（American Society of Anesthesiologists) grade I-III&#xD;
&#xD;
             6) Voluntary participation and informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1)The anesthesia method for cesarean section is general anesthesia or intraspinal&#xD;
             anesthesia, and epidural administration is used&#xD;
&#xD;
             2) Combined with other opioids during operation&#xD;
&#xD;
             3) High risk pregnancy (multiple pregnancy, in vitro pregnancy, etc.) or pregnancy&#xD;
             related complications (hypertension, preeclampsia, chorioamnionitis, etc.)&#xD;
&#xD;
             4) Times of previous cesarean section ≥ 3&#xD;
&#xD;
             5) BMI ≥ 50kg/m2 is not suitable for TAP block&#xD;
&#xD;
             6) Allergies or contraindications to the drugs involved in the study&#xD;
&#xD;
             7) Combined with operations other than tubal ligation and ovariectomy&#xD;
&#xD;
             8) Severe renal function impairment (SCR&gt;176 µ mol/L and/or blood urea nitrogen&gt;17.9&#xD;
             mmol/L), severe liver function impairment (ALT and/or aspartate aminotransferase&#xD;
             exceed 3 times the upper limit of normal value)&#xD;
&#xD;
             9) Increased risk of coagulation dysfunction or bleeding (PLT&lt;80 × 109/L or&#xD;
             international normalized ratio&gt; 1.5)&#xD;
&#xD;
             10) History of chronic pain or opiate abuse&#xD;
&#xD;
             11) Other clinical trials in the last three months&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Huang Nie, Doctor</last_name>
    <phone>13201630298</phone>
    <email>niehuang@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Fourth military medical university, Xijing Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shannxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>nie huang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huang Nie</name>
      <address>
        <city>Xi'an</city>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huang Nie</last_name>
      <phone>+862984775337</phone>
      <email>niehuang@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>December 26, 2022</study_first_submitted>
  <study_first_submitted_qc>January 16, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2023</study_first_posted>
  <last_update_submitted>June 6, 2023</last_update_submitted>
  <last_update_submitted_qc>June 6, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dexmedetomidine</keyword>
  <keyword>transversus abdominis plane block</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Agnosia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 28, 2022</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT05700045/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 28, 2022</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT05700045/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

